14266 Federal Register / Vol. 87, No. 49 / Monday, March 14, 2022 / Notices 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–22–22DF; Docket No. CDC–2022– 

0034] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing efforts to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other federal 

agencies to take this opportunity to 

comment on a proposed and/or 

continuing information collections, as 

required by the Paperwork Reduction 

Act of 1995. This notice invites 

comment on a proposed information 

collection project titled Assessing the 

Availability of COVID–19 Testing at 

U.S. Airports. This project is designed 

to collect information on the availability 

of testing for COVID–19 to travelers at 

U.S. airports. 

DATES: Written comments must be 

received on or before May 13, 2022. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2022– 

0034, by either of the following 

methods: 

• Federal eRulemaking Portal: 

regulations.gov. Follow the instructions 

for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS H21–8, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. CDC will post, without 

change, all relevant comments to 

regulations.gov. 

Please note: Submit all comments through 

the Federal eRulemaking portal 

(regulations.gov) or by U.S. mail to the 

address listed above. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 

instruments, contact Jeff Zirger, 

Information Collection Review Office, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS 

H21–8, Atlanta, Georgia 30329; phone: 

404–639–7570; Email: omb@cdc.gov. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. In addition, the PRA also 

requires federal agencies to provide a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each new 

proposed collection, each proposed 

extension of existing collection of 

information, and each reinstatement of 

previously approved information 

collection before submitting the 

collection to OMB for approval. To 

comply with this requirement, we are 

publishing this notice of a proposed 

data collection as described below. 

The OMB is particularly interested in 

comments that will help: 

(1) Evaluate whether the proposed 

collection of information is necessary for the 

proper performance of the functions of the 

agency, including whether the information 

shall have practical utility; 

(2) Evaluate the accuracy of the agency’s 

estimate of the burden of the proposed 

collection of information; 

(3) Enhance the quality, utility, and clarity 

of the information to be collected; 

(4) Minimize the burden of the collection 

of information on respondents, including 

through the use of automated collection 

techniques or other forms of information 

technology (e.g., permitting electronic 

submissions of responses); and 

(5) Assess information collection costs. 

Proposed Project 

Information Collection for Assessing 

the Availability of COVID–19 Testing at 

U.S. Airports—New—National Center 

for Emerging and Zoonotic Infectious 

Diseases (NCEZID), Centers for Disease 

Control and Prevention (CDC). 

Background and Brief Description 

The Centers for Disease Control and 

Prevention’s (CDC), National Center for 

Emerging and Zoonotic Infectious 

Diseases (NCEZID), Division of Global 

Migration and Quarantine (DGMQ), 

Quarantine and Border Health Services 

Branch (QBHSB) requests approval for a 

new information collection request. 

This project pertains to collecting 

information on the availability of testing 

for COVID–19 to travelers at U.S. 

airports. 

The respondents are airport directors 

or their designees at 522 airports in the 

continental United States, the District of 

Columbia, or any territory or possession 

of the United States. These airports 

serve passenger-carrying operations 

conducted on certified air carriers. This 

project will initially pilot with a sample 

of 100 airports and subsequently expand 

to include the remaining 422 Schedule 

A passenger-carrying U.S. or territorial 

airports following the initial rollout, for 

a total of 522 airports. The 100 sampled 

airports were selected based on the 

following criteria: (1) Having more than 

1,000 international arrivals in 2019, or 

(2) having a CDC quarantine station, or 

if not meeting one of the above criteria, 

and (3) ranking among the top in 

domestic arrival passenger volume for 

2019 (U.S. Bureau of Transportation). 

These airports represent 89% of 

domestic and international travel for 

2019. 

To achieve DGMQ’s mission, QBHSB 

works with domestic and international 

programs to protect the U.S. public by 

preventing importation of infectious 

disease through travel. Some U.S. 

airports have facilitated COVID–19 

testing locations for departing or 

arriving domestic and international 

travelers (passengers and crew). QBHSB 

seeks to regularly obtain comprehensive 

and updated information on COVID–19 

testing activities occurring at U.S. 

airports, which allows CDC to monitor 

trends in testing offered at airports. The 

information collected in this project will 

be used primarily to ascertain the scope 

of testing activities and to eventually 

provide information to the traveling 

public on testing availability at U.S. 

airports. Existing surveillance systems 

do not collect this type of information, 

thereby preventing CDC from 

monitoring airport testing trends and 

improving program effectiveness, 

particularly during an emergency 

response. 

Currently, CDC is requesting this data 

be sent by airport directors or their 

designees at least twice per year, with 

monthly reminder emails being sent to 

encourage response. The consequences 

of reducing this frequency would be the 

inability to obtain comprehensive and 

updated information in a timely manner 

which could affect program 

improvement. 

CDC requests OMB approval for an 

estimated 33,060 annual burden hours. 

There is no cost to the respondents 

other than their time. 


jspears on DSK121TN23PROD with NOTICES1
Federal Register / Vol. 87, No. 49 / Monday, March 14, 2022 / Notices 14267 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total 

burden 

(in hours) 

Airport directors or managers (All airports).COVID–19 Airport Testing Planner 

web form.

522 20 190/60 33,060 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2022–05300 Filed 3–11–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30Day–22–1105] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

In accordance with the Paperwork 

Reduction Act of 1995, the Centers for 

Disease Control and Prevention (CDC) 

has submitted the information 

collection request titled ‘‘One Health 

Harmful Algal Bloom System 

(OHHABS)’’ to the Office of 

Management and Budget (OMB) for 

review and approval. CDC previously 

published a ‘‘Proposed Data Collection 

Submitted for Public Comment and 

Recommendations’’ notice on November 

16, 2021 to obtain comments from the 

public and affected agencies. CDC did 

not receive comments related to the 

previous notice. This notice serves to 

allow an additional 30 days for public 

and affected agency comments. 

CDC will accept all comments for this 

proposed information collection project. 

The Office of Management and Budget 

is particularly interested in comments 

that: 

(a) Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

(b) Evaluate the accuracy of the 

agencies estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

(c) Enhance the quality, utility, and 

clarity of the information to be 

collected; 

(d) Minimize the burden of the 

collection of information on those who 

are to respond, including, through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses; and 

(e) Assess information collection 

costs. 

To request additional information on 

the proposed project or to obtain a copy 

of the information collection plan and 

instruments, call (404) 639–7570. 

Comments and recommendations for the 

proposed information collection should 

be sent within 30 days of publication of 

this notice to www.reginfo.gov/public/ 

do/PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. Direct written 

comments and/or suggestions regarding 

the items contained in this notice to the 

Attention: CDC Desk Officer, Office of 

Management and Budget, 725 17th 

Street NW, Washington, DC 20503 or by 

fax to (202) 395–5806. Provide written 

comments within 30 days of notice 

publication. 

Proposed Project 

One Health Harmful Algal Bloom 

System (OHHABS) (OMB Control No. 

0920–1105, Exp. 3/31/2022)— 

Revision—National Center for Emerging 

and Zoonotic Infectious Diseases 

(NCEZID), Centers for Disease Control 

and Prevention (CDC). 

Background and Brief Description 

The Centers for Disease Control and 

Prevention (CDC), National Center for 

Emerging and Zoonotic Infectious 

Diseases (NCEZID) requests a three-year 

Revision for the One Health Harmful 

Algal Bloom System (OHHABS) for 

harmful algal bloom (HAB) and HABassociated illness surveillance. 

HABs are the rapid growth of algae or 

cyanobacteria (also called blue-green 

algae) that can cause harm to people, 

animals, or the local ecology. Toxins 

from HABs include some of the most 

potent natural chemicals; these toxins 

can contaminate surface water used for 

recreation and drinking, as well as food 

sources. HABs pose a threat to both 

humans and animals. Human and 

animal illnesses from exposures to 

HABs in fresh and marine waters have 

been documented throughout the 

United States. Animal illness may be an 

indicator of bloom toxicity; thus, it is 

necessary to provide a One Health 

approach for reporting HAB-associated 

illnesses and events. 

HABs are an emerging public health 

concern. For 2016—2019, 22 states 

adopted use of the OHHABS and 

entered 669 reports, including 

information about 452 human illnesses 

and at least 481 animal illnesses 

associated with HAB events. Of the 669 

HAB event reports, 84% were associated 

with freshwater, resulting in 428 (95%) 

of human illnesses. In these freshwater 

settings, the most common signs and 

symptoms reported include generalized 

(e.g., headache, fever, fatigue), 

gastrointestinal, and dermatologic. 

Known adverse health effects from 

HABs in marine waters include 

respiratory illness and seafood 

poisoning. In 2007, 15 persons were 

affected with respiratory illness from 

exposures to brevetoxins, an algal toxin, 

during a Florida red tide. From 2007– 

2011, HAB-associated foodborne 

exposures were identified for 273 case 

reports of human illness through a 

separate five-year data collection effort 

with a subset of states. Of these reports, 

248 reported ciguatera fish poisoning 

(CFP) or poisoning by other toxins in 

seafood, including saxitoxin and 

brevetoxin. A review of national 

outbreak data reported to CDC for the 

time period 1998–2015, identified 

outbreaks CFP as the second most 

common cause of fish-associated 

foodborne disease outbreaks in the 

United States, among those outbreaks 

with a confirmed etiology. For this time 

period, 227 CFP outbreaks resulted in 

894 illnesses and 96 hospitalizations. 

For 2016–2018, an additional 47 

outbreak investigations implicated CFP, 

resulting in 147 illnesses and 12 

hospitalizations. 

Domestic animal, livestock, and 

wildlife HAB-associated illnesses have 

also been documented in the United 

States. Between 2016 and 2019, 79 cases 

of domestic pet illness were reported to 

OHHABS, with 39% (n=31) resulting in 

death. During the same time period, 

there were at least 53 livestock illnesses 

and 349 wildlife illnesses reported. The 


jspears on DSK121TN23PROD with NOTICES1